Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.03M | 9.22M | 7.38M | 6.92M | 6.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.49M | 49.58M | 43.11M | 30.58M | 19.82M |
| Operating Income | -47.49M | -49.58M | -43.11M | -30.58M | -19.82M |
| Income Before Tax | -40.41M | -46.35M | -36.02M | -24.68M | -13.91M |
| Income Tax Expenses | 153.00K | 41.10K | 92.10K | 78.70K | 70.00K |
| Earnings from Continuing Operations | -40.56M | -46.40M | -36.11M | -24.76M | -13.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 615.00K | 791.20K | 724.10K | 491.70K | 302.00K |
| Net Income | -39.94M | -45.60M | -35.39M | -24.27M | -13.67M |
| EBIT | -47.49M | -49.58M | -43.11M | -30.58M | -19.82M |
| EBITDA | -47.11M | -48.28M | -43.08M | -30.55M | -19.49M |
| EPS Basic | -0.63 | -0.72 | -0.56 | -0.39 | -0.22 |
| Normalized Basic EPS | -0.39 | -0.45 | -0.35 | -0.24 | -0.13 |
| EPS Diluted | -0.63 | -0.72 | -0.56 | -0.39 | -0.22 |
| Normalized Diluted EPS | -0.39 | -0.45 | -0.35 | -0.24 | -0.13 |
| Average Basic Shares Outstanding | 63.23M | 63.07M | 62.90M | 62.87M | 62.64M |
| Average Diluted Shares Outstanding | 63.23M | 63.07M | 62.90M | 62.87M | 62.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |